Bank of New York Mellon’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Bank of New York Mellon’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,361	Closed	-$164K	–	4726
2022 Q1	$164K	Hold	4,361	–	–	﹤0.01%	4300
2021 Q4	$245K	Hold	4,361	–	–	﹤0.01%	4182
2021 Q3	$315K	Hold	4,361	–	–	﹤0.01%	4016
2021 Q2	$418K	Sell	4,361 -1,784	-29%	-$197K	﹤0.01%	3847
2021 Q1	$909K	Sell	6,145 -77	-1%	-$14K	﹤0.01%	3385
2020 Q4	$870K	Buy	6,222 +1,652	+36%	+$268K	﹤0.01%	3334
2020 Q3	$694K	Buy	4,570 +1,247	+38%	+$203K	﹤0.01%	3327
2020 Q2	$584K	Buy	+3,323	New	+$556K	﹤0.01%	3398
2019 Q1	–	Sell	-84	Closed	-$3K	–	4269
2018 Q4	$3K	Sell	84 -2	-2%	-$145	﹤0.01%	4221
2018 Q3	$6K	Hold	86	–	–	﹤0.01%	4237
2018 Q2	$7K	Sell	86 -23	-21%	-$2.01K	﹤0.01%	4201
2018 Q1	$9K	Buy	109 +23	+27%	+$3.42K	﹤0.01%	4293
2017 Q4	$64K	Hold	86	–	–	﹤0.01%	4166
2017 Q3	$25K	Sell	86 -8	-9%	-$2.18K	﹤0.01%	4196
2017 Q2	$24K	Buy	94 +3	+3%	+$806	﹤0.01%	4217
2017 Q1	$30K	Buy	91 +7	+8%	+$3.24K	﹤0.01%	4195
2016 Q4	$50K	Sell	84 -6	-7%	-$6.34K	﹤0.01%	4130
2016 Q3	$101K	Sell	90 -60	-40%	-$64.7K	﹤0.01%	4043
2016 Q2	$164K	Buy	150 +2	+1%	+$2.51K	﹤0.01%	3949
2016 Q1	$190K	Buy	148 +43	+41%	+$61.3K	﹤0.01%	3804
2015 Q4	$258K	Buy	105 +27	+35%	+$41.4K	﹤0.01%	3782
2015 Q3	$87K	Hold	78	–	–	﹤0.01%	4140
2015 Q2	$79K	Sell	78 -149	-66%	-$161K	﹤0.01%	4088
2015 Q1	$231K	Sell	227 -17	-7%	-$56.1K	﹤0.01%	3859
2014 Q4	$815K	Buy	244 +8	+3%	+$24.5K	﹤0.01%	3413
2014 Q3	$685K	Buy	236 +26	+12%	+$86K	﹤0.01%	3507
2014 Q2	$799K	Buy	+210	New	+$791K	﹤0.01%	3424

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $78.9M AUM 38.67% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Bank of New York Mellon's NBSE Position: Q2 2022 in Review

Bank of New York Mellon sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2022, closing a stake of 4,361 shares — an estimated $164K sold.

Bank of New York Mellon first reported a position in NBSE in Q2 2014 and held it in 27 quarters. The position peaked at $909K in Q1 2021. 43 funds tracked by Wall St. Rank hold NBSE as of Q2 2022.

Bank of New York Mellon reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Bank of New York Mellon sold 4,361 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $164K.
Bank of New York Mellon first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and held it in 27 quarters.
Bank of New York Mellon's NeuBase Therapeutics, Inc. Common Stock position peaked at $909K in Q1 2021.
43 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.